Roivant Sciences (ROIV) financial statements
Roivant Sciences reported revenue of $8M in fiscal 2026, down 19.1% a year over 5 years.
Net income was -$300M and the operating margin -6235.7%, against -4500.5% in 2021.
Free cash flow was -$759M.
The diluted share count rose 10% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Roivant Sciences's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $24M | $55M | $32M | $33M | $29M | $8M |
| Cost of revenue | $2M | $9M | $3M | $2M | $911,000 | $1M |
| Gross profit | $22M | $46M | $28M | $31M | $28M | $7M |
| Research and development | $237M | $483M | $454M | $440M | $550M | $682M |
| Selling, general and admin | $260M | $775M | $601M | $687M | $591M | $610M |
| Operating income | -$1.1B | -$1.4B | -$907M | $4.5B | -$1.0B | -$515M |
| Interest expense | $3M | $7M | $28M | $35M | — | — |
| Pre-tax income | -$899M | -$924M | -$885M | $4.6B | -$682M | -$265M |
| Income tax | $2M | $369,000 | $4M | $22M | $48M | $133M |
| Net income | -$809M | -$845M | -$1.0B | $4.3B | -$172M | -$300M |
| EPS (diluted) | -$1.28 | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
| Diluted shares | 630M | 670M | 713M | 831M | 725M | 694M |
| Gross margin | 91.4% | 83.8% | 90.4% | 95.1% | 96.9% | 84.4% |
| Operating margin | -4500.5% | -2444.8% | -2875.9% | 13746.9% | -3453.3% | -6235.7% |
| Net margin | -3400.9% | -1528.9% | -3200.2% | 13294.2% | -592.0% | -3629.2% |
Balance sheet
Fiscal years, from Roivant Sciences's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $2.1B | $2.1B | $1.7B | $6.5B | $4.9B | $4.3B |
| Receivables | $11M | $4M | $30M | $4M | — | — |
| Inventory | — | $0 | $3M | $35M | — | — |
| Total current assets | $2.2B | $2.1B | $1.8B | $6.7B | $5.0B | $5.2B |
| Property, plant and equipment | $15M | $26M | $39M | $15M | $12M | $12M |
| Total assets | $2.6B | $2.6B | $2.4B | $7.2B | $5.4B | $5.7B |
| Total current liabilities | $219M | $184M | $272M | $267M | $149M | $281M |
| Long-term debt | $170M | $210M | — | — | — | — |
| Total liabilities | $528M | $524M | $782M | $774M | $250M | $416M |
| Shareholders' equity | $1.8B | $1.7B | $1.2B | $6.0B | $4.7B | $4.5B |
| Net debt | -$1.9B | -$1.9B | -$1.6B | -$6.5B | -$2.7B | -$1.4B |
Cash flow
Fiscal years, from Roivant Sciences's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$552M | -$678M | -$843M | -$765M | -$839M | -$750M |
| Capital spending | $6M | $17M | $13M | $1M | $5M | $8M |
| Free cash flow | -$558M | -$695M | -$856M | -$767M | -$844M | -$759M |
| Stock-based compensation | $85M | $565M | $218M | $200M | $289M | $346M |
| Share buybacks (net) | — | — | $0 | $0 | -$1.3B | — |
| Free cash flow margin | -2344.8% | -1257.4% | -2715.1% | -2343.6% | -2905.2% | -9183.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ROIV.
Open ROIV in InvestinglyQuestions
What was Roivant Sciences's revenue in 2026?
$8M in fiscal 2026, from its 10-K filing.
How much free cash flow does Roivant Sciences generate?
-$759M in fiscal 2026 (operating cash flow minus capital spending).
From Roivant Sciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.